TY - JOUR
T1 - A Survival Score for Patients Receiving Palliative Irradiation for Locally Advanced Lung Cancer
AU - Rades, Dirk
AU - Käsmann, Lukas
AU - Schild, Steven E.
AU - Janssen, Stefan
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - The present study aimed to create a survival score for patients requiring palliative irradiation for locally advanced lung cancer to facilitate personalized treatment. Using 3 prognostic factors, 3 groups were designed with a 6-month survival rate of 13%, 47%, and 82%, respectively. This new score will enable physicians to estimate the remaining lifespan of lung cancer patients requiring palliative local irradiation. Background Many patients with locally advanced lung cancer cannot withstand aggressive curative treatment and are referred for palliative irradiation. The goals of palliative radiotherapy are control of local disease and symptoms. Treatment should be tailored to each patient's situation and remaining lifespan. The present study aimed to create a survival score for patients requiring palliative irradiation for locally advanced lung cancer. Patients and Methods The data from 125 patients receiving palliative irradiation for locally advanced lung cancer were evaluated for survival. To identify the predictors of survival, 9 factors were investigated, including gender, age, performance status, smoking history, T stage, N stage, M stage, histologic type, and tumor location. Factors showing significant or borderline significant association with survival on multivariate analysis were included in the score. The 6-month survival rates were divided by 10 to calculate the points associated with the individual prognostic factors. The points obtained from each prognostic factor were summed to compile the patient's total score. Results On multivariate analysis, N stage (P = .005) and M stage (P = .033) were significantly associated with survival, and the Karnofsky performance score achieved borderline significance (P = .052). The patient scores ranged from 10 to 17 points for the 6-month survival rates. Using the patient scores, 3 survival groups were designed: 10 to 11, 12 to 14, and 15 to 17 points. The corresponding 6-month survival rates were 13%, 47% and 82% (P < .001). The corresponding 12-month survival rates were 8%, 19%, and 69%. Conclusion With this new score, physicians can estimate the remaining lifespan of patients requiring palliative irradiation for locally advanced lung cancer. This score should ideally be validated in an independent cohort of patients.
AB - The present study aimed to create a survival score for patients requiring palliative irradiation for locally advanced lung cancer to facilitate personalized treatment. Using 3 prognostic factors, 3 groups were designed with a 6-month survival rate of 13%, 47%, and 82%, respectively. This new score will enable physicians to estimate the remaining lifespan of lung cancer patients requiring palliative local irradiation. Background Many patients with locally advanced lung cancer cannot withstand aggressive curative treatment and are referred for palliative irradiation. The goals of palliative radiotherapy are control of local disease and symptoms. Treatment should be tailored to each patient's situation and remaining lifespan. The present study aimed to create a survival score for patients requiring palliative irradiation for locally advanced lung cancer. Patients and Methods The data from 125 patients receiving palliative irradiation for locally advanced lung cancer were evaluated for survival. To identify the predictors of survival, 9 factors were investigated, including gender, age, performance status, smoking history, T stage, N stage, M stage, histologic type, and tumor location. Factors showing significant or borderline significant association with survival on multivariate analysis were included in the score. The 6-month survival rates were divided by 10 to calculate the points associated with the individual prognostic factors. The points obtained from each prognostic factor were summed to compile the patient's total score. Results On multivariate analysis, N stage (P = .005) and M stage (P = .033) were significantly associated with survival, and the Karnofsky performance score achieved borderline significance (P = .052). The patient scores ranged from 10 to 17 points for the 6-month survival rates. Using the patient scores, 3 survival groups were designed: 10 to 11, 12 to 14, and 15 to 17 points. The corresponding 6-month survival rates were 13%, 47% and 82% (P < .001). The corresponding 12-month survival rates were 8%, 19%, and 69%. Conclusion With this new score, physicians can estimate the remaining lifespan of patients requiring palliative irradiation for locally advanced lung cancer. This score should ideally be validated in an independent cohort of patients.
UR - http://www.scopus.com/inward/record.url?scp=84994509565&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2016.05.010
DO - 10.1016/j.cllc.2016.05.010
M3 - Journal articles
C2 - 27341791
AN - SCOPUS:84994509565
SN - 1525-7304
VL - 17
SP - 558
EP - 562
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 6
ER -
